- ( +41 ) 78 834 6262
- info@tesct.org
- Rainweg 7,CH-3066 Berne-Stettlen.
- English
The TransEuropeanStemCellTherapy Society (TESCT) is a network of key players in the “StemCell Area”, with a membership encompassing clinics, patient or ganisations, professional socio-ethical societies and industry partners. By its growing portfolio of projects, research and policy papers, as well as events, TESCT emphasizes the importance of continued interaction with the European and Trans European Institutions to build strong health policies.
An important goal for the TESCT Society is the better exploitation of so-called Real World Evidence (RWE) data. Patients suffering neurological degenerative diseases could receive timelier access to safer and more efficient therapies and could become important partners in the regulation and pricing of medicines.RWE data is a category of disease-specific data being collected outside of the predefined area of clinical trials. It can come from clinical practice, prescription databases, patient registries, social media or pharmacovigilance – the monitoring process carried out on drugs that have obtained marketing authorization in the EU.
The TESCT Society is fostering exchange between different disciplines and associations,promoting prevention and lobbying governments for enhanced research and treatments, in order to improve the quality of life of people affected by brain disorders.
Neurologist and MS researcher Gavin Giovannoni presented convincing arguments from the MS Brain Health project on the importance of early diagnosis in MS. This could lead to more efficient treatment and higher quality of life for patients. Health economist Gisela Kobelt provided proof along the same lines as Prof. Giovannoni with her presentation on the new Cost of Illness study – completed by 17,000 MS patients from 16 European countries. Dr. Kobelt called for health care costs to be assessed as investments from a societal point of view. Neurologist Maura Pugliatti further substantiated these points with her presentation on the Value of Treatment (VoT) project, a multi-stakeholder initiative led by the European Brain Council (EBC). VoT proposes a model of integrated care for brain disorders – such as MS – that can close the treatment gap in Europe.
TESCT is raising awareness and encouraging education on regenerative medicine with individual is ed therapies and gene editing and the repercussions of neurological and mental health conditions on society as a whole.
Copyright © 2019 TESCT. Developed by BayState InfoTech.
